Aldeyra resubmits reproxalap NDA for dry eye disease after positive Phase 3 trial

Aldeyra Therapeutics, Inc.

Resubmission includes positive results from FDA-requested symptom trial.
Phase 3 dry eye chamber trial met primary endpoint (ocular discomfort, P=0.004).
If approved, reproxalap would be first chronic dry eye therapy with acute symptom and redness data.
FDA review expected within 6 months of acceptance; acknowledgment in 30 days.
Reproxalap showed acute activity in reducing dry eye symptoms and ocular redness in trials.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.